MACUGEN Drug Patent Profile
✉ Email this page to a colleague
When do Macugen patents expire, and when can generic versions of Macugen launch?
Macugen is a drug marketed by Bausch And Lomb Inc and is included in one NDA.
The generic ingredient in MACUGEN is pegaptanib sodium. Additional details are available on the pegaptanib sodium profile page.
Summary for MACUGEN
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 1 |
Clinical Trials: | 44 |
Patent Applications: | 1,822 |
Drug Prices: | Drug price information for MACUGEN |
DailyMed Link: | MACUGEN at DailyMed |
Recent Clinical Trials for MACUGEN
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Oslo University Hospital | Phase 4 |
Retina Vitreous Associates of Florida | N/A |
Vision Research Foundation | Phase 2 |
Anatomical Therapeutic Chemical (ATC) Classes for MACUGEN
US Patents and Regulatory Information for MACUGEN
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Bausch And Lomb Inc | MACUGEN | pegaptanib sodium | INJECTABLE;INTRAVITREAL | 021756-001 | Dec 17, 2004 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for MACUGEN
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Bausch And Lomb Inc | MACUGEN | pegaptanib sodium | INJECTABLE;INTRAVITREAL | 021756-001 | Dec 17, 2004 | ⤷ Try a Trial | ⤷ Try a Trial |
Bausch And Lomb Inc | MACUGEN | pegaptanib sodium | INJECTABLE;INTRAVITREAL | 021756-001 | Dec 17, 2004 | ⤷ Try a Trial | ⤷ Try a Trial |
Bausch And Lomb Inc | MACUGEN | pegaptanib sodium | INJECTABLE;INTRAVITREAL | 021756-001 | Dec 17, 2004 | ⤷ Try a Trial | ⤷ Try a Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for MACUGEN
See the table below for patents covering MACUGEN around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Australia | 6383900 | ⤷ Try a Trial | |
Canada | 2221318 | LIGANDS OLIGONUCLEOTIDIQUES AYANT UNE AFFINITE ELEVEE POUR LES FACTEURS DE CROISSANCE (HIGH AFFINITY OLIGONUCLEOTIDE LIGANDS TO GROWTH FACTORS) | ⤷ Try a Trial |
Australia | 732961 | ⤷ Try a Trial | |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for MACUGEN
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
0957929 | 20/2006 | Austria | ⤷ Try a Trial | PRODUCT NAME: PEGAPTANIB UND SALZE DAVON; REGISTRATION NO/DATE: EU/1/05/325/001 20060131 |
0957929 | SPC024/2006 | Ireland | ⤷ Try a Trial | SPC024/2006:, EXPIRES: 20210130 |
0957929 | C 2007 038 | Romania | ⤷ Try a Trial | PRODUCT NAME: 5'-ESTERUL((2'-DEOXI-2'-FLUORO)C-GM-GM-A-A-(2'-DEOXI-2'-FLUORO)U-(2'-DEOXI-2'-FLUORO)C-AM-GM-(2'-DEOXI-2'-FLUORO)U-GM-AM-AM-(2'-DEOXI-2'-FLUORO)U-GM-(2'-DEOXI-2'-FLUORO)C-(2'-DEOXI-2'-FLUORO)U-(2'-DEOXI-2'-FLUORO)U-AM-(2'-DEOXI-2'-FLUORO)U-AM-(2'-DEOXI-2'-FLUORO)C-AM-(2'-DEOXI-2'-FLUORO)U-(2'-DEOXI-2'-FLUORO)C-(2'-DEOXI-2'-FLUORO)C-GM-(3'-3')-DT)CUALFA,ALFA'-[(1S)-1-[(5-(FOSFOONOXI)PENTIL]CARBAMOIL]PENTAN-1,5-DIIL]BIS(IMINOCARBONIL)]BIS[OMEGA-METOXIPOLI(OXIETAN-1,2-DIIL)], DE PREFERINTA SUB FORMA SARII DE SODIU - PEGAPTANIB, DE PREFERINTA SUB FORMA SARII DESODIU; NATIONAL AUTHORISATION NUMBER: EU/1/05/325/001; DATE OF NATIONAL AUTHORISATION: 20060131; NUMBER OF FIRST AUT [...] |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |